Nuvectis Pharma, Inc.
NVCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875558
No open-market purchases or sales by Nuvectis Pharma, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $189.0M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Nuvectis Pharma, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 31 | 31 | 0 |
| Shares | 1.05M | 1.32M | +271.4K (+25.9%) |
| Value | $6.60M | $7.15M | +$546.0K (+8.3%) |
New holders (7)
Institutions that held Nuvectis Pharma, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Oppenheimer & Co Inc | 25,000 | $135.3K | 0.00% |
| Squarepoint Ops LLC | 19,071 | $103.2K | 0.00% |
| Cubist Systematic Strategies, LLC | 6,294 | $34.1K | 0.00% |
| Point72 Asia (Singapore) Pte. Ltd. | 4,479 | $24.2K | 0.01% |
| R Squared Ltd | 310 | $1.68K | 0.00% |
| BNP Paribas Arbitrage, SA | 115 | $622 | 0.00% |
| Point72 (DIFC) Ltd | 49 | $265 | 0.00% |
Sold out (7)
Institutions that held Nuvectis Pharma, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Iridian Asset Management LLC | 55,380 | $348.3K |
| Renaissance Technologies LLC | 15,800 | $99.4K |
| Citigroup Inc | 8,887 | $55.9K |
| Catalyst Funds Management Pty Ltd | 900 | $5.66K |
| Tower Research Capital LLC (TRC) | 588 | $3.70K |
| FMR LLC | 402 | $2.53K |
| Nisa Investment Advisors, LLC | 12 | $75 |